LESD
MCID: LTT002
MIFTS: 34

Letterer-Siwe Disease (LESD)

Aliases & Classifications for Letterer-Siwe Disease

MalaCards integrated aliases for Letterer-Siwe Disease:

Name: Letterer-Siwe Disease 56 74 71
Histiocytosis X, Acute Disseminated 56
Histiocytosis, Langerhans-Cell 71
L-S Disease; Lesd 56
L-S Disease 56
Lesd 56

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
letterer-siwe disease:
Inheritance autosomal recessive inheritance


Summaries for Letterer-Siwe Disease

MalaCards based summary : Letterer-Siwe Disease, also known as histiocytosis x, acute disseminated, is related to langerhans cell histiocytosis and obsolete: letterer-siwe disease, and has symptoms including fever The drugs Methotrexate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and lymph node, and related phenotypes are edema and pain

Wikipedia : 74 Letterer-Siwe disease is one of the four recognized clinical syndromes of Langerhans cell histiocytosis... more...

More information from OMIM: 246400

Related Diseases for Letterer-Siwe Disease

Diseases related to Letterer-Siwe Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
# Related Disease Score Top Affiliating Genes
1 langerhans cell histiocytosis 13.1
2 obsolete: letterer-siwe disease 12.6
3 hashimoto-pritzker syndrome 11.5
4 histiocytosis 10.9
5 reticuloendotheliosis, x-linked 10.8
6 thrombocytopenia 10.3
7 pneumonia 10.3
8 malignant histiocytosis 10.3
9 pfeiffer syndrome 10.1
10 otitis media 10.1
11 retinal detachment 10.1
12 ceroid storage disease 10.1
13 chediak-higashi syndrome 10.1
14 hemophagocytic lymphohistiocytosis, familial, 1 10.1
15 mental retardation, skeletal dysplasia, and abducens palsy 10.1
16 omenn syndrome 10.1
17 hydrops, lactic acidosis, and sideroblastic anemia 10.1
18 exanthem 10.1
19 chronic myelomonocytic leukemia 10.1
20 protein-losing enteropathy 10.1
21 pneumocystosis 10.1
22 leukemia 10.1
23 pancytopenia 10.1
24 diarrhea 10.1
25 obstructive jaundice 10.1
26 lymphadenitis 10.1
27 gaucher's disease 10.1
28 splenic infarction 10.1
29 agammaglobulinemia 10.1
30 dermatitis 10.1
31 chronic granulomatous disease 10.1
32 pyoderma 10.1
33 macular retinal edema 10.1
34 retinal degeneration 10.1
35 monocytic leukemia 10.1
36 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.1
37 measles 10.1
38 subacute monocytic leukemia 10.1
39 aphthous stomatitis 10.1
40 alopecia 10.1
41 cytomegalic inclusion disease 10.1
42 hemophagocytic reticulosis 10.1
43 splenomegaly 10.1
44 obsolete: hand-schuller-christian disease 10.1

Graphical network of the top 20 diseases related to Letterer-Siwe Disease:



Diseases related to Letterer-Siwe Disease

Symptoms & Phenotypes for Letterer-Siwe Disease

Human phenotypes related to Letterer-Siwe Disease:

31 (show all 43)
# Description HPO Frequency HPO Source Accession
1 edema 31 frequent (33%) HP:0000969
2 pain 31 frequent (33%) HP:0012531
3 dermatological manifestations of systemic disorders 31 frequent (33%) HP:0001005
4 polydipsia 31 occasional (7.5%) HP:0001959
5 skin rash 31 occasional (7.5%) HP:0000988
6 diabetes insipidus 31 occasional (7.5%) HP:0000873
7 abnormality of femur morphology 31 occasional (7.5%) HP:0002823
8 abnormality of the ribs 31 occasional (7.5%) HP:0000772
9 growth hormone deficiency 31 occasional (7.5%) HP:0000824
10 abnormal lung morphology 31 occasional (7.5%) HP:0002088
11 progressive neurologic deterioration 31 occasional (7.5%) HP:0002344
12 abnormality of bone marrow cell morphology 31 occasional (7.5%) HP:0005561
13 abnormality of the lymph nodes 31 occasional (7.5%) HP:0002733
14 abnormal liver parenchyma morphology 31 occasional (7.5%) HP:0030146
15 abnormal spleen morphology 31 occasional (7.5%) HP:0025408
16 abnormal pelvis bone morphology 31 occasional (7.5%) HP:0040163
17 soft tissue neoplasm 31 occasional (7.5%) HP:0031459
18 abnormal skull morphology 31 occasional (7.5%) HP:0000929
19 dysarthria 31 very rare (1%) HP:0001260
20 pathologic fracture 31 very rare (1%) HP:0002756
21 osteolysis 31 very rare (1%) HP:0002797
22 dysmetria 31 very rare (1%) HP:0001310
23 bone cyst 31 very rare (1%) HP:0012062
24 pituitary hypothyroidism 31 very rare (1%) HP:0008245
25 adrenocorticotropic hormone deficiency 31 very rare (1%) HP:0011748
26 giant cell tumor of bone 31 very rare (1%) HP:0011847
27 gonadotropin deficiency 31 very rare (1%) HP:0008213
28 increased circulating prolactin concentration 31 very rare (1%) HP:0000870
29 fever 31 HP:0001945
30 dyspnea 31 HP:0002094
31 anemia 31 HP:0001903
32 pallor 31 HP:0000980
33 irritability 31 HP:0000737
34 pulmonary infiltrates 31 HP:0002113
35 abnormality of the skeletal system 31 HP:0000924
36 thrombocytopenia 31 HP:0001873
37 jaundice 31 HP:0000952
38 neutropenia 31 HP:0001875
39 seborrheic dermatitis 31 HP:0001051
40 abdominal distention 31 HP:0003270
41 encephalopathy 31 HP:0001298
42 hepatosplenomegaly 31 HP:0001433
43 stomatitis 31 HP:0010280

Symptoms via clinical synopsis from OMIM:

56
Misc:
fever
onset in first year

Heme:
anemia
thrombocytopenia
neutropenia

Neuro:
encephalopathy
infantile irritability

Abdomen:
distended abdomen

Lab:
histiocytosis x (eosinophilic granuloma)
histiocytic infiltration of the liver, spleen and lymph nodes

Resp:
dyspnea

Skin:
pallor
jaundice
stomatitis
seborrhea
diffuse papulo-vesicular rash
more
G I:
hepatosplenomegaly

Radiology:
pulmonic infiltration
lytic osseous lesions

Clinical features from OMIM:

246400

UMLS symptoms related to Letterer-Siwe Disease:


fever

Drugs & Therapeutics for Letterer-Siwe Disease

Drugs for Letterer-Siwe Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
2
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
3
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3 147-94-4, 65-46-3 6253
4
Cladribine Approved, Investigational Phase 2, Phase 3 4291-63-8 20279
5
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
6
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
7
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
8 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
9
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
10
Vinblastine Approved Phase 2, Phase 3 865-21-4 13342 241903
11
Indomethacin Approved, Investigational Phase 2, Phase 3 53-86-1 3715
12
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
13
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
14
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
15
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
16
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
17
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
18
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
19 Antirheumatic Agents Phase 3
20 Folic Acid Antagonists Phase 2, Phase 3
21 Vitamin B Complex Phase 2, Phase 3
22 Vitamin B9 Phase 2, Phase 3
23 Dermatologic Agents Phase 2, Phase 3
24 Folate Phase 2, Phase 3
25 Antimetabolites Phase 3
26 Anti-Infective Agents Phase 3
27 Antiviral Agents Phase 2, Phase 3
28 Hormone Antagonists Phase 2, Phase 3
29 Anti-Inflammatory Agents Phase 2, Phase 3
30 Antineoplastic Agents, Hormonal Phase 2, Phase 3
31 glucocorticoids Phase 2, Phase 3
32 Hormones Phase 2, Phase 3
33 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
34 Analgesics, Non-Narcotic Phase 2, Phase 3
35 Analgesics Phase 2, Phase 3
36 2-chloro-3'-deoxyadenosine Phase 2, Phase 3
37 Tocolytic Agents Phase 2, Phase 3
38 Methylprednisolone Acetate Phase 2, Phase 3
39 Cyclooxygenase Inhibitors Phase 2, Phase 3
40 Antimitotic Agents Phase 2, Phase 3
41 Immunoglobulins, Intravenous Phase 2, Phase 3
42 Rho(D) Immune Globulin Phase 2, Phase 3
43 gamma-Globulins Phase 2, Phase 3
44 Immunologic Factors Phase 2, Phase 3
45 Immunosuppressive Agents Phase 2, Phase 3
46 Alkylating Agents Phase 2, Phase 3
47 Thymoglobulin Phase 2, Phase 3
48
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
49
Thioguanine Approved Phase 2 154-42-7 2723601
50
Etanercept Approved, Investigational Phase 2 185243-69-0

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis Completed NCT00488605 Phase 3 Prednisone, Vinblastin, 6-mercaptopuroine;Leucovorin, Methotrexate, Vinblastine, Prednisone
2 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis Recruiting NCT02205762 Phase 2, Phase 3 Prednisone;Vinblastine;mercaptopurine;INDOMETHACIN;Methotrexate;Cytosine Arabinoside;2-chlorodeoxyadenosine
3 Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115) Recruiting NCT02670707 Phase 3 Cytarabine;Vinblastine/prednisone
4 In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
5 The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
6 Transplantation Using Umbilical Cord And Placental Blood Unknown status NCT00008164 Phase 2
7 Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH) Completed NCT00588536 Phase 2 Methotrexate;6-Thioguanine;Leucovorin Calcium
8 Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis Completed NCT02389400 Phase 2 methotrexate
9 A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis Completed NCT01395004 Phase 2 GSK2110183
10 Treatment of Resistant Langerhans Cell Histiocytosis With Etanercept (ENBREL, IMMUNEX, SEATTLE) Completed NCT00048373 Phase 2 Etanercept
11 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
12 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
13 Cytarabine Monotherapy for Adult Patients With Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04121819 Phase 2 Cytarabine
14 Thalidomide, Cyclophosphamide and Dexamethasone for Adult Patients With Recurrent/Refractory Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study Recruiting NCT04120519 Phase 2 thalidomide combined with dexamethasone and cyclophosphamide
15 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders Recruiting NCT02425904 Phase 2 Clofarabine
16 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes Recruiting NCT03526250 Phase 2 Palbociclib
17 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
18 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
19 Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial Recruiting NCT03270020 Phase 2 Denosumab 70 MG/ML [Xgeva]
20 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib;Larotrectinib Sulfate
21 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex Recruiting NCT03213665 Phase 2 Tazemetostat
22 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations Recruiting NCT03210714 Phase 2 Erdafitinib
23 NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients With Solid Tumors Recruiting NCT03213678 Phase 2 Samotolisib
24 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;Samotolisib;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
25 The Prospective Non-randomized Phase II Clinical Trial of Vemurafenib in Combination With Cytarabine and 2-chlorodeoxyadenosine in Children With Langerhans-cell Hisitocytosis With BRAF V600E Mutation Recruiting NCT03585686 Phase 2 Vemurafenib;Cytarabine;2-chlorodeoxyadenosine
26 Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Patients With Pulmonary Langerhans Cell Histiocytosis and Impairment of Lung Function Active, not recruiting NCT01473797 Phase 2 Cladribine
27 A Phase II Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
28 Cord Blood Ex-Vivo MSC Expansion Plus Fucosylation to Enhance Homing and Engraftment Active, not recruiting NCT03096782 Phase 2 Busulfan;Clofarabine;Cyclophosphamide;Fludarabine;Melphalan;Mycophenolate Mofetil;Tacrolimus
29 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations Not yet recruiting NCT04195555 Phase 2 Ivosidenib
30 A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders. Not yet recruiting NCT04079179 Phase 2 Cobimetinib
31 NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations Suspended NCT03698994 Phase 2 Ulixertinib
32 Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis Terminated NCT00618540 Phase 2 fludarabine phosphate;melphalan
33 Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis Withdrawn NCT01796405 Phase 2 Clofarabine
34 A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy Completed NCT00890747 Phase 1 sunitinib malate
35 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
36 Functional and Genetical Characterization of Pulmonary Langerhans Cell Histiocytosis: Diagnostic and Therapeutical Implications. Unknown status NCT03093727
37 Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis Unknown status NCT03052101
38 CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES Unknown status NCT00483925
39 Epidemiology of Adult Adult Pulmonary Langerhans Cell Histiocytosis - A Multicenter Cohort Study Completed NCT01225601
40 Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement Completed NCT02608619
41 Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung Function. A Multicenter Retrospective Study Completed NCT01651507
42 Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies Completed NCT00898755
43 Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis Completed NCT00276757 leucovorin calcium;methotrexate;prednisolone;vinblastine sulfate
44 Evaluation of Exercise Capacity and Mechanisms of Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis Completed NCT02665546
45 Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH) Recruiting NCT04100408
46 The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Recruiting NCT02402244
47 Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies Recruiting NCT01652092 Alemtuzumab 0.3 mg;Cyclophosphamide;Busulfan;Fludarabine phosphate 40 mg;Melphalan;Alemtuzumab 0.2 mg;Busulfan;Fludarabine phosphate 30 mg;MESNA
48 CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease Recruiting NCT01966367 Early Phase 1
49 The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation Terminated NCT00008216

Search NIH Clinical Center for Letterer-Siwe Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Genetic Tests for Letterer-Siwe Disease

Anatomical Context for Letterer-Siwe Disease

MalaCards organs/tissues related to Letterer-Siwe Disease:

40
Bone, Lung, Lymph Node, Liver, Skin, Spleen, Monocytes

Publications for Letterer-Siwe Disease

Articles related to Letterer-Siwe Disease:

(show top 50) (show all 352)
# Title Authors PMID Year
1
Familial occurrence of Letterer-Siwe disease. 61 56
5018627 1972
2
U.S. mortality from Letterer-Siwe disease, 1960-1964. 61 56
5663744 1968
3
FAMILIAL OCCURRENCE OF LETTERER-SIWE DISEASE. 61 56
14084326 1963
4
Familial Letterer-Siwe disease. Report of a case. 61 56
14037540 1962
5
Langerhans cell histiocytosis. 56
7608790 1995
6
Familial occurrence of histiocytosis. 56
300046 1977
7
Familial pulmonary histiocytosis-X. 56
4695633 1973
8
Genetic determination of acute disseminated histiocytosis X. 56
5444399 1970
9
A unique manifestation of Langerhans cell histiocytosis: Diagnostic and therapeutic considerations of atypical cases. 61
29940687 2018
10
Multidisciplinary approach in a case of Hand-Schüller-Christian disease with maxillary involvement. 61
29418009 2018
11
"Histiocytosis X" - A Rare Case Report. 61
27891484 2016
12
Gastrointestinal: Letterer Siwe disease: An uncommon gastrointestinal presentation. 61
26757250 2016
13
Congenital self-healing reticulohistiocytosis: an underreported entity. 61
27163913 2016
14
Localized Langerhans cell histiocytosis masquerading as Brodie's abscess in a 2-year-old child: a case report. 61
27065773 2016
15
Solitary extragnathic langerhans cell histiocytosis - a rare case. 61
25954715 2015
16
Solitary eosinophilic granuloma of mandibular condyle: literature review and report of a rare case. 61
25861187 2015
17
Hand schuller christian disease: a rare case report with oral manifestation. 61
25738095 2015
18
Langerhans-cell histiocytosis (LCH) a presentation of two siblings with two different entities. 61
26191478 2015
19
Diagnosis and management of langerhans cell histiocytosis. 61
25281259 2014
20
A rare occurrence of Langerhans cell histiocytosis in an adult. 61
25948998 2014
21
Narrowband ultraviolet B light in Langerhans cell histiocytosis: a case report. 61
24224945 2014
22
29 year-old male with seizure and syncope. Intracerebral Langerhans cell histiocytosis. 61
23587144 2013
23
[Letterer Siwe disease in an adult: a case report]. 61
23336233 2012
24
Operative case of Langerhans'cell histiocytosis of the skull with dural invasion. An immunohystochemical study of ki-67 expression of eosinophilic granuloma: case report and review of the literature. 61
22415385 2012
25
A rare case of langerhans cell histiocytosis of the gastrointestinal tract. 61
22493557 2012
26
Eosinophilic granuloma: resolution of lesion after biopsy. 61
22134295 2011
27
Analysis of histiocytosis deaths in the US and recommendations for incidence tracking. 61
21688746 2010
28
Letterer-Siwe disease associated with chronic myelomyonocytic leukemia: a fortuitous association? 61
20372775 2010
29
[Langerhans cell histiocytosis]. 61
19828161 2009
30
Oral Langerhans cell histiocytosis in Malaysian children: a 40-year experience. 61
19486369 2009
31
[Langerhans cell histiocytosis: Letterer-Siwe disease - the importance of dermatological diagnosis in two cases]. 61
19851674 2009
32
Langerhans cell histiocytosis, a case of Letterer Siwe disease. 61
19785312 2009
33
Langerhans cell histiocytosis: literature review and descriptive analysis of oral manifestations. 61
19218906 2009
34
Langerhans cell histiocytosis presented as bilateral otitis media and mastoiditis. 61
18365596 2008
35
[Clinical and pathologic features of Letterer-Siwe disease: a case report and review]. 61
18072575 2007
36
A case report of langerhans histiocytosis presenting sequentially over a 21-year period with Letterer-Siwe disease, hand-Schuller-Christian disease and eosinophillic granuloma of bone. 61
17114962 2006
37
Disseminated crusted papules in a newborn. 61
16875431 2006
38
Splenic infarction in Letterer-Siwe disease. 61
15910461 2005
39
Spontaneous regression of supratentorial intracerebral Langerhans' cell histiocytosis. 61
15326050 2004
40
Congenital self-healing reticulohistiocytosis: report of a case and review of the literature. 61
15124855 2004
41
Quiz. Langerhans cell histiocytosis (Letterer-Siwe disease). 61
17642901 2003
42
[One neonatal patient with letterer-siwe disease]. 61
14751071 2003
43
[Eosinophilic granuloma of the temporal bone. Case report and literature review]. 61
12717600 2003
44
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. 61
12121233 2002
45
Bilateral multifocal uveal juvenile xanthogranuloma in a young boy with systemic disease. 61
12107521 2002
46
Self-healing congenital Langerhans cell histiocytosis presenting as neonatal papulovesicular eruption. 61
11907857 2001
47
Letterer siwe disease. 61
17664795 2001
48
Langerhans cell histiocytosis of the thyroid gland. A case report. 61
11015983 2000
49
Histiocytosis of the temporal bone. 61
23119694 2000
50
Electron microscopic study of Langerhans cell histiocytosis. 61
10935343 2000

Variations for Letterer-Siwe Disease

Expression for Letterer-Siwe Disease

Search GEO for disease gene expression data for Letterer-Siwe Disease.

Pathways for Letterer-Siwe Disease

GO Terms for Letterer-Siwe Disease

Sources for Letterer-Siwe Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....